The development of resistance to antimicrobials threatens to reverse the changes in public health that have occurred over the last 70 years or so. This is a global problem. While it is tempting to feel relatively comfortable with the situation, living as we do in the Western World, unless antimicrobial resistance (AMR) is tackled, it is very likely at some point to wreak havoc here too. Who now doesn’t regard the risk of a hospital acquired infection in themselves, a friend or a relative as a significant possibility? Or who now is not more concerned over minor cuts and grazes?
AMR is a much-discussed topic, and this edition of our BioTuesday series aims to provide attendees a better understanding of a range of issues, including the factors holding the development of new medicines back and how the field will develop.
Our speakers will discuss matters such as:
The background to the crisis of AMR
Has the situation worsened due to a lack of education and early action?
What are the latest government policies around AMR – is this enough?
What is the government and private funding landscape like for AMR research?
What role does Machine Learning plan in the research of potential solutions to this crisis?
Where does the UK stand compared to the rest of the world?
How does the use of antibiotics in farming impact the problem, and what is the farming industry doing to make the required changes?
What needs to change to get big pharma engaged?
Is a combination approach the answer to AMR?
17.30 – 18.00 Registration and networking (tea and coffee served)
18.00 – 18.05 Welcome by John Harris, CEO of OBN & Geoff Davison, CEO of Bionow
18.05 – 18.15 Welcome & Introduction to the topic by Chris Doherty, Alderley Park
18.15 – 18.35 Keynote: Dr Peter Jackson, Executive Director of the AMR Centre
18.35 - 18.55 Keynote: Dr Fiona Marston, Director of the Centre of Excellence in Infectious Diseases Research
18.55 - 19.15 Keynote: Dr Richard Fitzgerald , Director of The Royal Liverpool and Broadgreen University Hospitals NHS Trust
19.15 – 20.00 Company Presentations from:
Dr. Deborah O'Neil, Chief Executive Officer and Scientific Officer, NovaBiotics
Dr Fiona Rudkin, CEO, mycoBiologics
Heather Graz, Commercial Development Manager, Neem Biotech
Conrad Lichtenstein, CSO, Nemesis Bioscience
Paul Ko Ferrigno, Founder & Director, metaLinear: 'Engineering proteomes to discover, validate and drug protein-protein interactions in antibiotic-resistant bacteria'
20.10 - 20.40 Q&A with speakers and audience, hosted by Chris Doherty
20.40 – 21.30 Networking with drinks and canapes served